JPMorgan Downgrades BioMimetic Therapeutics (BMTI) to Neutral
Tweet
Share
E-mailGet Alerts BMTI Hot Sheet
Price: $9.49 --0%
Rating Summary:
0 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 16
Rating Summary:
0 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 10 | New: 16
Join SI Premium – FREE
JPMorgan downgraded BioMimetic Therapeutics (NASDAQ: BMTI) from Overweight to Neutral with a $5 price target.
For more ratings news on BioMimetic Therapeutics click here and for the rating history of BioMimetic Therapeutics click here.
Shares of BioMimetic Therapeutics closed at $5.12 yesterday.
For more ratings news on BioMimetic Therapeutics click here and for the rating history of BioMimetic Therapeutics click here.
Shares of BioMimetic Therapeutics closed at $5.12 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Gerdau S.A. (GGBR4:BZ) (GGB) to Neutral
- Keefe, Bruyette & Woods Downgrades Allstate (ALL) to Underperform
- Macquarie Downgrades Kuaishou Technology (1024:HK) to Underperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
